Author

Ágnes Milassin

COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS
COMPARATIVE OUTCOMES AND SAFETY OF BUDESONIDE-MMX VERSUS PREDNISOLONE FOR ULCERATIVE COLITIS AND POSSIBLE GENETICAL PREDICTORS OF SIDE-EFFECTS

Ágnes Milassin  et al.

THE RISK OF MALIGNANCY OF DIAGNOSTIC CATEGORIES DEFINED BY PAPANICOLAOU SOCIETY OF CYTOPATHOLOGY SYSTEM IN EUS-FNA SAMPLING OF SOLID PANCREATIC LESIONS
THE RISK OF MALIGNANCY OF DIAGNOSTIC CATEGORIES DEFINED BY PAPANICOLAOU SOCIETY OF CYTOPATHOLOGY SYSTEM IN EUS-FNA SAMPLING OF SOLID PANCREATIC LESIONS

Ágnes Milassin  et al.

INCIDENCE AND PREDICTORS OF POST-COLONOSCOPY COLORECTAL CANCER – POPULATION-BASED RETROSPECTIVE STUDY
INCIDENCE AND PREDICTORS OF POST-COLONOSCOPY COLORECTAL CANCER – POPULATION-BASED RETROSPECTIVE STUDY

Ágnes Milassin  et al.

USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY
USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY

Ágnes Milassin  et al.

PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET
PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET

Ágnes Milassin  et al.

Item 1 - 5 / 5
1